At AAOS, Large Joint Makers Are Making It Personal

At AAOS’ 2012 meeting, one attention-grabbing strategy centered on the personalization of large joint implants to match the specific anatomies of patients. Several large joint manufacturers have introduced tools for achieving “custom fits” for new joints, knees in particular. Advances in robotics and customized manufacturing are enabling smaller companies to take personalization to the next step. MAKO featured its MAKOplasty Total Hip Arthroplasty (MAKOplasty THA), an advancement of its partial knee MAKOplasty procedure. In another approach toward customizing knee surgeries, ConforMIS manufactures a line of knee implants that are custom made for each individual patient.

Over the past few quarters, large joint manufacturers have been reporting stable but relatively flat sales growth, forcing makers of hip and knee implants to try to grab market share from rivals. Traditionally, this isn’t an easy task as large joint surgeons are notoriously loyal to their favorite implants, so medical device manufacturers continue to pursue new techniques and approaches to help them win over surgeons and purchasing hospitals.

At last month’s American Academy of Orthopaedic Surgeons 2012 Annual Meeting, one attention-grabbing strategy centered on the personalization of large...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from In Vivo

Deals In Depth: June 2025

 
• By 

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.